

## Adherium Exhibiting at AAAAI 2024 Annual Meeting

### Highlights:

- Adherium will exhibit at The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting from 23 – 25 February 2024 in Washington, DC.
- The AAAAI Annual Meeting 2024 unites more than 7,000 allergy, asthma and immunology health professionals from the United States, Canada, and 72 other countries.
- Adherium will aim to strengthen partnerships with healthcare professionals and asthma/COPD medical groups in attendance, supporting its core focus to serve large populations of asthma and COPD patients in the United States.

**Melbourne, Australia – 22 February 2024:** Adherium Limited (“Adherium” or “the Company”; ASX:ADR), a leader in respiratory eHealth, remote monitoring and data management solutions will be exhibiting and meeting with commercial partners at the [American Academy of Allergy, Asthma & Immunology's 2024 Annual Meeting](#) in Washington, DC on 23-25 February 2024 at booth #384.

As part of sessions organised by AAAAI on electronic monitoring technology and at Adherium's booth, there will be live demonstrations of the Company's Hailie® platform, illustrating its ability to remotely monitor adherence and physiological parameters such as inspiratory flow.

Whilst in attendance, Adherium will aim to further strengthen its partnerships with key health system providers and asthma medical groups, in alignment with its plan to service large populations of asthma/COPD patients in the United States and other key international health markets too.

**Adherium CEO, Dr. Paul Mastoridis, said:** *“Our team is excited to be attending and demonstrating our unique digital adherence system at the AAAAI 2024 Annual Meeting – an important meeting of our valued industry peers, fellow innovators, and customers too. Our Hailie® platform system helps reduce emergency room visits, hospitalisations, exacerbations as well as healthcare costs associated with asthma and COPD. Our unique technology is of key interest to leading international medical experts who will be attending this event.”*

Adherium has achieved significant milestones in advancing respiratory health technology in the past year. Most notably, the Company has successfully obtained FDA approval and brought to market three new Hailie Smartinhalers with physiological parameters to help address patient inhaler technique. These state-of-the-art Hailie Smartinhalers will be showcased at the AAAAI Annual Meeting.

Adherium has also made substantial enhancements to its healthcare provider dashboards within the Hailie portal. These dashboards offer healthcare professionals improved insights into patient adherence and physiological parameters, enabling more informed decision-making in the management of asthma and COPD.



## ASX Release

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organisation in its field. Its membership is comprised of more than 7,000 health professionals in the United States, Canada and 72 other countries.

For more details, please visit: <https://annualmeeting.aaaai.org/>

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

### **Investor Enquiries**

Dr. Paul Mastoridis  
Adherium Limited  
Chief Executive Officer  
[investors@adherium.com](mailto:investors@adherium.com)

### **Media Enquiries:**

Haley Chartres  
HACK  
Director  
[haley@hck.digital](mailto:haley@hck.digital)

### **About Adherium (ASX: ADR)**

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at [www.adherium.com](http://www.adherium.com)